IOM report favors government role in CME

Share this article:
A recent Institute of Medicine (IOM) report focused on reforming CME offers a new catalyst for change: a public-private institute that would alter the way education is financed, regulated and evaluated.

As soon as practical, members of the IOM committee wrote, the secretary of Health and Human Services should work to plan a public-private institute to help bring about a shift in CME, incorporating existing components but transitioning to continuing professional development (CPD), an educational model focused more on outcomes. IOM favors government involvement only as a catalyst. “We needed a third party with clout to convene the right people on these issues, and [the government] would be able to create some accountability,” said committee chair Gail Warden during a webinar hosted by the Alliance for CME and other national CME groups.

But John Kamp, executive director, Coalition for Healthcare Communication, said he sees in the report a threat to “nationalize” CME. “More bureaucracy and federal spending are the last things we need in CME, especially in this age of huge federal deficits and the incredible resources needed to deliver the promise of healthcare reform to the American public.”

Warden, of the extent of government's role on the webinar, said: “This is not something we're just trying to turn over to government. We're trying to get government attention, get them involved.” In their recommendations, IOM also set the stage for academic medical centers to play a lead role in forming the institute: “They need to own CPD, and not just in their own particular profession but across the professions,” Warden said.

Industry input would still be valued. “We obviously cannot ignore pharma and device manufacturers and the important role that they play…and we obviously have to recognize that much of that is done by education providers that are connected to those organizations,” he said.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets